Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**BK002** is an oral, fixed-dose synbiotic medical-nutrition product developed by BiOkuris for dietary management of **irritable bowel syndrome**, including constipation-predominant, diarrhea-predominant, and mixed-subtype disease. The formulation combines fungal chitin-glucan, *Lactobacillus acidophilus* NCFM, and vitamin D3. It is intended to support microbiota balance and intestinal-barrier function and to reduce gastrointestinal symptoms through a gut-brain-axis-oriented, multi-component approach. BiOkuris reported positive results from its 14-week randomized Vitabiotic study and has described BK002 as ready for licensing and distribution; it is not presented as an approved pharmaceutical medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BK002.